Tsauo J, Noh SY, Shin JH, et al. - Researchers undertook this multicentre retrospective study to assess whether retrograde transvenous obliteration (RTO) affords an effective and safe option for variceal rebleeding prevention in patients suffering from hepatocellular carcinoma (HCC). Participants were 79 patients with HCC who had RTO for the prevention of variceal rebleeding. During follow-up, seven patients (9.6%) suffered rebleeding. The 6-week and 1-year actuarial likelihoods of patients remaining free of rebleeding were estimated to be 90.8±3.6% and 88.6±4.1%, respectively. A median survival of 12.6 months was reported. A total of 12 (16.4%) and 13 patients (17.8%) experienced new or worsening ascites and oesophageal varices, respectively, during the follow-up span. Follow-up revealed occurrence of overt hepatic encephalopathy in one patient (1.4%). Overall, findings showed effectiveness as well as safety of RTO in preventing variceal rebleeding in HCC patients.